09:02 EDT Insmed (INSM) up 10% at $150 after announcing results from Phase 3b ENCORE study
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed Reports Positive Phase 3b ENCORE ARIKAYCE Results
- Insmed announces ‘positive’ results from Phase 3b ENCORE study
- Insmed price target lowered to $175 from $208 at Wells Fargo
- Liquidia price target raised to $51 from $44 at Wells Fargo
- United Therapeutics price target raised to $486 from $466 at Wells Fargo